Pharma exec Shkreli pleads not guilty to securities fraud

NEW YORK (AP) — A pharmaceutical executive who came under fire for jacking up the price of a lifesaving malaria medication has pleaded not guilty to new charges in his securities fraud case.

Martin Shkreli (SHKREHL’-ee) appeared Monday in federal court in New York City. He declined to speak to reporters as he left the courthouse.

A revised indictment filed last week alleged Shkreli and his former attorney Evan Greebel schemed to defrauded potential investors of his former drug company Retrophin Inc., based in San Diego. Greebel also pleaded not guilty Monday.

Before his arrest, Shkreli already was reviled because another drug company he owned raised the price of Daraprim by 5,000 percent.

Shkreli’s attorney has said the securities fraud prosecution is based on a “flawed theory.”

A trial is expected early next year.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s